HC Wainwright Has Positive Opinion of NKTR FY2026 Earnings

Nektar Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright raised its earnings outlook, narrowing its projected FY2026 loss to $7.06 per share from $7.49, while maintaining a Buy rating and $185 price target. Its forecast turns positive at $0.59 per share in 2030, though it expects losses through 2029.
  • Nektar reported a quarterly loss of $1.63 per share, better than analysts’ $2.07 loss estimate, but revenue of $9.39 million fell short of the $10.27 million consensus.
  • Analyst opinions are mixed: MarketBeat rates the stock a Moderate Buy, with a consensus price target of $130.33; ratings range from Buy to Sell.
  • Five stocks we like better than Nektar Therapeutics.

Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Stock analysts at HC Wainwright increased their FY2026 EPS estimates for Nektar Therapeutics in a research report issued to clients and investors on Monday, November 16th. HC Wainwright analyst A. He now expects that the biopharmaceutical company will earn ($7.06) per share for the year, up from their previous forecast of ($7.49). HC Wainwright currently has a "Buy" rating and a $185.00 target price on the stock. The consensus estimate for Nektar Therapeutics' current full-year earnings is ($7.53) per share. HC Wainwright also issued estimates for Nektar Therapeutics' Q4 2026 earnings at ($2.38) EPS, Q1 2027 earnings at ($2.45) EPS, Q2 2027 earnings at ($1.01) EPS, Q3 2027 earnings at ($2.62) EPS, Q4 2027 earnings at ($2.29) EPS, FY2027 earnings at ($8.40) EPS, FY2028 earnings at ($9.23) EPS, FY2029 earnings at ($6.08) EPS and FY2030 earnings at $0.59 EPS.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The biopharmaceutical company reported ($1.63) EPS for the quarter, topping analysts' consensus estimates of ($2.07) by $0.44. The business had revenue of $9.39 million for the quarter, compared to analyst estimates of $10.27 million. Nektar Therapeutics had a negative net margin of 339.67% and a negative return on equity of 29.31%.

Other analysts also recently issued research reports about the company. UBS Group assumed coverage on Nektar Therapeutics in a research note on Monday, October 12th. They issued a "neutral" rating and a $53.00 price target on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Nektar Therapeutics in a report on Friday, August 28th. BTIG Research reaffirmed a "buy" rating and set a $178.00 price objective on shares of Nektar Therapeutics in a research report on Friday, October 9th. Wedbush decreased their price objective on Nektar Therapeutics from $80.00 to $50.00 and set a "neutral" rating for the company in a report on Wednesday, September 23rd. Finally, Wall Street Zen downgraded Nektar Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $130.33.

Read Our Latest Stock Report on NKTR

Nektar Therapeutics Trading Down 1.5%

Shares of NASDAQ NKTR opened at $35.91 on Wednesday. The firm has a market cap of $1.23 billion, a PE ratio of -5.56 and a beta of 1.44. Nektar Therapeutics has a 1-year low of $33.40 and a 1-year high of $109.00. The company has a fifty day moving average price of $46.93 and a 200 day moving average price of $64.55.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. grew its holdings in shares of Nektar Therapeutics by 171.9% in the 3rd quarter. Goldman Sachs Group Inc. now owns 621,249 shares of the biopharmaceutical company's stock valued at $37,614,000 after acquiring an additional 392,759 shares in the last quarter. Orbimed Advisors LLC acquired a new stake in shares of Nektar Therapeutics in the first quarter valued at about $19,786,000. Two Seas Capital LP increased its position in shares of Nektar Therapeutics by 8.2% in the third quarter. Two Seas Capital LP now owns 3,345,978 shares of the biopharmaceutical company's stock valued at $202,582,000 after acquiring an additional 253,744 shares during the last quarter. Braidwell LP increased its position in shares of Nektar Therapeutics by 112.7% in the second quarter. Braidwell LP now owns 473,617 shares of the biopharmaceutical company's stock valued at $33,063,000 after acquiring an additional 250,916 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in Nektar Therapeutics during the second quarter worth about $6,706,000. Institutional investors and hedge funds own 75.88% of the company's stock.

Nektar Therapeutics News Roundup

Here's some of the latest news about NKTR:

  • Positive Sentiment: HC Wainwright lifted its EPS forecasts across 2026–2029, reflecting smaller projected losses, and raised its 2030 estimate to $0.59 from $0.35, implying a move to profitability in that year. The firm maintained its Buy rating and $185 price target. HC Wainwright rating and outlook
  • Neutral Sentiment: Canaccord Genuity lowered its target to $149 from $153 but kept a Buy rating. The reduced target is a modest negative, while the continued Buy stance remains supportive.
  • Negative Sentiment: Despite the improved estimates, HC Wainwright still projects substantial losses through 2029. That continuing cash- and earnings-pressure outlook may limit the impact of the longer-term profitability forecast on the stock.

About Nektar Therapeutics

(Get Free Report)

Nektar Therapeutics is a clinical-stage biopharmaceutical company based in San Francisco, California. It discovers and develops medicines, with a current focus on treatments for autoimmune and inflammatory diseases. Its lead investigational program, rezpegaldesleukin (REZPEG), is designed to stimulate regulatory T cells, which help regulate immune responses. Nektar is studying the candidate in clinical trials for immune-mediated conditions; it is not an approved medicine. Founded in 1990 as Inhale Therapeutic Systems, the company later adopted the Nektar name as it expanded its drug-development work.

Featured Stories

Earnings History and Estimates for Nektar Therapeutics (NASDAQ:NKTR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Nektar Therapeutics Right Now?

Before you consider Nektar Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nektar Therapeutics wasn't on the list.

While Nektar Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines